会议召开地点： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 5 月 4 日(星期四)至 5 月 8 日(星期一)16:00 前登录上证路演 中心网站首页点击"提问预征集"栏目或通过公司投资者关系邮箱 (IR@medicilon.com.cn)进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 证券代码：688202 证券简称：美迪西 公告编号：2023-025 上海美迪西生物医药股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩暨现金分 红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 5 月 9 日(星期二)下午 13:00-14:30 上海美迪西生物医药股份有限公司（以下简称"公司"）于 2023 年 4 月 26 日在上海证券交易所网站（www.sse.com.cn）披露了公司 2022 ...

Financial Performance - Revenue for Q3 2022 reached ¥497,418,300.72, an increase of 65.12% compared to the same period last year[9] - Net profit attributable to shareholders for Q3 2022 was ¥115,484,893.70, reflecting a growth of 70.20% year-over-year[9] - Basic earnings per share for Q3 2022 were ¥1.33, a 70.51% increase compared to the same period last year[12] - Operating profit for Q3 2022 was ¥318,017,736.11, compared to ¥208,383,652.10 in Q3 2021, indicating an increase of about 52.6%[48] - Net profit for Q3 2022 was ¥278,088,622.66, up from ¥183,378,709.53 in Q3 2021, reflecting a growth of approximately 51.5%[48] - Total comprehensive income for the period reached ¥278,088,622.66, an increase from ¥180,954,043.22 in the previous year, representing a growth of approximately 53.6%[51] - Basic and diluted earnings per share increased to ¥3.20, compared to ¥2.08 in the same period last year, reflecting a growth of 53.8%[51] Research and Development - R&D investment totaled ¥35,725,712.71 in Q3 2022, up 63.13% from the previous year[12] - The proportion of R&D investment to revenue was 7.18%, a decrease of 0.09 percentage points compared to the previous year[12] - Research and development expenses for the first three quarters of 2022 were ¥86,932,416.88, compared to ¥56,019,615.62 in the same period of 2021, showing an increase of about 55.5%[46] Assets and Liabilities - Total assets at the end of Q3 2022 amounted to ¥2,164,255,770.73, representing a 20.67% increase from the end of the previous year[12] - Total assets as of Q3 2022 amounted to ¥2,164,255,770.73, compared to ¥1,793,571,687.19 at the end of Q3 2021, marking an increase of about 20.6%[42] - Total liabilities for Q3 2022 were ¥627,370,921.55, up from ¥466,062,292.99 in Q3 2021, representing a growth of approximately 34.6%[42] - The total current assets increased to ¥1,004,841,976.07 from ¥892,036,545.84 year-over-year[36] - The total non-current assets reached ¥1,159,413,794.66, up from ¥901,535,141.35 in the previous year, indicating a growth of approximately 28.6%[40] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥47,413,600.74, a decline of 123.59% compared to the previous year[12] - Cash inflow from operating activities totaled ¥988,084,165.61, up from ¥800,472,828.02, indicating a year-over-year increase of 23.4%[55] - Net cash outflow from operating activities was ¥47,413,600.74, a decline from a net inflow of ¥201,011,355.90 in the previous year[55] - Cash flow from investment activities showed a net outflow of ¥197,659,556.49, compared to a net outflow of ¥214,994,530.27 last year, indicating a slight improvement[55] - The company received cash from the recovery of investments amounting to ¥320,000,000.00, with no such cash inflow reported in the previous year[55] - The company paid out ¥85,608,529.50 in dividends and interest, compared to ¥39,060,000.00 in the same period last year, marking an increase of 119.9%[56] Shareholder Information - The total number of common shareholders at the end of the reporting period is 6,523[24] - The largest shareholder, Chen Jinzhan, holds 13,611,623 shares, representing 15.66% of the total shares[24] - The top ten shareholders include significant institutional investors such as China Industrial Bank and China Construction Bank, holding 4,168,714 and 2,000,097 shares respectively[28] - The number of shares held by the top ten shareholders accounts for a substantial portion of the company's equity, indicating concentrated ownership[24] - The company has a total of 0 preferred shareholders with restored voting rights at the end of the reporting period[24] Operational Efficiency - The company reported a significant increase in operational efficiency and profitability due to enhanced management and integrated advantages[19] - The company's cash and cash equivalents decreased to ¥183,683,143.32 from ¥412,367,523.00 year-over-year[36] - Accounts receivable increased significantly to ¥470,056,077.77 from ¥212,503,512.34 year-over-year[36] - Inventory rose to ¥210,436,899.39 compared to ¥83,479,898.47 in the previous year[36] - The company reported a significant increase in accounts payable, which rose to ¥203,028,173.08 from ¥120,098,402.38, reflecting a growth of about 69.1%[42] - The company's cash and cash equivalents increased, contributing to improved liquidity and financial stability[40] - The impact of exchange rate changes on cash and cash equivalents was a positive ¥12,559,754.65, contrasting with a negative impact of ¥1,198,804.59 in the previous year[56] - The company reported a significant increase in cash received from operating activities related to tax refunds, totaling ¥34,917,572.79, compared to ¥17,456,037.29 last year, representing a growth of 100.5%[55]

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 20%[12]. - The company's operating revenue for the first half of the year reached ¥742,876,868.98, representing a 53.16% increase compared to the same period last year[29]. - The net profit attributable to shareholders was ¥162,603,728.96, up 43.77% year-over-year, while the net profit after deducting non-recurring gains and losses increased by 40.39% to ¥153,987,629.99[29]. - The basic and diluted earnings per share both rose to ¥1.87, reflecting a growth of 43.85% compared to the previous year[29]. - The company's total assets increased by 9.90% to ¥1,971,162,298.69, while net assets attributable to shareholders rose by 6.57% to ¥1,414,767,188.86[29]. - A total of 196.83 million CNY in revenue was reported, with a net profit of 51.21 million CNY for the first half of 2022[120]. - The company achieved a revenue of 743 million RMB in the first half of 2022, representing a year-on-year growth of 53.16%[132]. - The revenue from the preclinical research segment grew by 79.16% year-on-year, reaching 402.28 million RMB[135]. Research and Development - The company has provided a performance guidance for the second half of 2022, expecting a revenue growth of 25% compared to the first half[12]. - The company plans to invest RMB 100 million in new technology for drug development to improve efficiency and reduce time to market[12]. - The company has completed 42 new drug and generic drug projects that have been approved by NMPA for clinical trials in the first half of 2022, with 5 projects approved by the U.S. FDA and Australia's TGA for clinical trials[45]. - The company has developed advanced technologies in drug discovery, including asymmetric synthesis, chiral separation, and computer-aided drug design (CADD), improving the efficiency of chiral drug development[46]. - The company has established a comprehensive evaluation system for non-clinical safety research of oligonucleotide drugs and mRNA vaccines[131]. - The company has developed a comprehensive non-clinical evaluation system for stem cell therapies, with an investment of ¥6 million and cumulative investment of approximately ¥4.99 million[61]. - The company has established a comprehensive platform for new drug clinical research applications (IND), enhancing its operational efficiency[54]. - The company has established a technical platform for non-clinical safety evaluation of mRNA vaccines, which will support future product development and market entry[66]. Market Expansion and Strategy - The company is expanding its market presence in Europe, targeting a 30% increase in sales in that region by the end of 2022[12]. - The company has completed a strategic acquisition of a biotech firm for RMB 200 million, enhancing its R&D capabilities[12]. - The company has established a strong brand image among clients, enhancing its ability to attract new business opportunities[41]. - The company has actively enhanced its R&D capabilities and service quality, contributing to the robust growth in operating revenue despite pandemic challenges[29]. - The company has established a professional service network in major cities, enhancing its market presence in China's innovative drug sector[128]. Workforce and Talent Management - The number of R&D personnel increased to 2,454, up from 1,684 in the same period last year, representing a growth of 45.7%[124]. - R&D personnel accounted for 86.62% of the total workforce, slightly up from 85.48% year-on-year[124]. - Total compensation for R&D personnel reached RMB 16,726.87 million, an increase of 51.8% from RMB 11,014.36 million in the previous year[124]. - The company faces risks related to talent retention and rising personnel costs, which could impact profitability if not managed effectively[140]. Compliance and Risk Management - The company is committed to maintaining compliance with regulatory standards, ensuring all new products meet the required safety and efficacy benchmarks[12]. - The company has identified potential risks in supply chain disruptions, which could impact production capacity[12]. - The company faces risks related to high employee turnover, which could impact long-term operations and development[4]. - Regulatory changes in the pharmaceutical industry may pose risks to the company's operations if it fails to adapt its strategies accordingly[8]. - The ongoing impact of the COVID-19 pandemic continues to present challenges for market expansion and project execution[10]. Environmental Management - The company has established internal procedures for waste management and pollution control, ensuring compliance with environmental standards[181]. - The company utilizes secondary biological treatment facilities and disinfection pools for wastewater management, meeting local discharge standards[181]. - The company has implemented measures to control noise pollution, ensuring compliance with industrial noise emission standards[181]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[188]. Innovation and Technology Development - The company has established a PDX model with 30 strains, enhancing the drug efficacy evaluation system, which is expected to significantly increase profit margins in future projects[76]. - The company has developed a robust LC-MS/MS quantitative bioanalysis platform for large biomolecule drugs, demonstrating high specificity, precision, and accuracy[70]. - The company has established a continuous flow chemistry laboratory, achieving kilogram-level production of active pharmaceutical ingredients and intermediates[32]. - The company has developed methods for assessing the immunogenicity of mRNA products, contributing to the establishment of internal technical standards[66]. Corporate Governance - The company has implemented two phases of equity incentive plans, benefiting 413 employees to enhance team cohesion and core competitiveness[135]. - The lock-up agreements are designed to align the interests of management with those of shareholders[200]. - The implementation of these lock-up periods reflects the company's commitment to corporate governance and shareholder value[200].

Financial Performance - The company's revenue for Q1 2022 was ¥355,988,685.97, representing a year-over-year increase of 65.79%[7] - Net profit attributable to shareholders for Q1 2022 was ¥77,191,634.76, reflecting a growth of 71.09% compared to the same period last year[7] - Basic earnings per share for Q1 2022 were ¥1.24, up 69.86% from the previous year[7] - Total revenue for Q1 2022 reached ¥355,988,685.97, a significant increase of 65.8% compared to ¥214,726,795.49 in Q1 2021[32] - Net profit for Q1 2022 was ¥77,191,634.76, compared to ¥47,403,100.16 in Q1 2021, representing a growth of 62.9%[36] - The total comprehensive income attributable to the parent company owners for the current period is 77,191,634.76, compared to 45,118,700.74 in the previous period, indicating strong overall performance[38] Cash Flow and Investments - The net cash flow from operating activities was -¥50,973,115.14, a decline of 328.82% year-over-year, primarily due to increased payments for experimental animals and slower customer payments[7][15] - Cash inflow from operating activities totaled 271,911,405.00, compared to 192,131,224.75 in the previous period, reflecting a growth of approximately 41.5%[43] - The net cash flow from operating activities decreased to -50,973,115.14 from 22,276,276.28 in the previous period, indicating a shift to negative cash flow[43] - Cash outflow from investing activities was 256,481,733.48, compared to 75,808,870.78 in the previous period, showing a substantial increase in investment expenditures[44] - The net cash flow from investing activities was -151,229,082.73, indicating a significant increase in cash used for investments compared to the previous period[44] - The cash and cash equivalents at the end of the period decreased to 204,839,450.81 from 408,281,006.51 in the previous period, reflecting a decline of approximately 50%[44] Assets and Liabilities - Total assets at the end of Q1 2022 amounted to ¥1,872,150,004.15, an increase of 4.38% from the end of the previous year[10] - Non-current assets totaled ¥956,287,302.74, an increase from ¥901,535,141.35 in the previous period[30] - Current liabilities remained stable at ¥383,956,446.71, slightly up from ¥383,662,450.66[30] - Deferred income tax liabilities increased to ¥25,496,054.84 from ¥22,162,759.89, marking a rise of 15.4%[32] - The company's fixed assets increased to CNY 438,272,262.22 from CNY 410,559,535.62, marking an increase of approximately 6.7%[27] Research and Development - R&D investment totaled ¥23,419,279.52, which is a 52.49% increase year-over-year, indicating a focus on enhancing R&D capabilities[10][15] - The proportion of R&D investment to revenue was 6.58%, a decrease of 0.57 percentage points compared to the previous year[10] - Research and development expenses for Q1 2022 were ¥23,419,279.52, compared to ¥15,358,165.05 in Q1 2021, reflecting a 52.5% increase[36] - The company plans to continue enhancing its R&D service capabilities and expanding its laboratory capacity to support future growth[15] Shareholder Information - The company plans to issue A-shares to specific investors as approved in meetings held on February 10 and February 28, 2022, to enhance capital for future growth[24] - The total number of shares held by the top ten unrestricted shareholders amounts to 12,000,000 shares, with the largest shareholder holding 3,034,138 shares[20] - The company has established a consistent action relationship among key shareholders, which may influence strategic decisions moving forward[23] Market and Growth Strategy - The company signed a significant number of new orders, driven by increasing recognition of its R&D service capabilities[12] - The company is actively pursuing market expansion and new product development strategies as part of its growth initiatives[24] - The company's accounts receivable increased to CNY 285,173,457.53 from CNY 212,503,512.34, reflecting a growth of about 34.2% year-over-year[27] - Inventory levels rose to CNY 139,081,069.83, up from CNY 83,479,898.47, indicating an increase of approximately 66.7% compared to the previous year[27] - The company reported a significant increase in prepayments, which rose to CNY 65,046,571.03 from CNY 36,553,409.61, reflecting an increase of approximately 78.2%[27]

Financial Performance - The company's operating revenue for 2021 reached ¥1,167,261,647.83, representing a 75.28% increase compared to ¥665,955,931.75 in 2020[21]. - Net profit attributable to shareholders for 2021 was ¥282,222,910.23, a significant increase of 118.12% from ¥129,386,307.58 in 2020[21]. - The net profit after deducting non-recurring gains and losses was ¥271,073,976.25, up 119.53% from ¥123,478,266.11 in the previous year[21]. - Cash flow from operating activities for 2021 was ¥452,936,579.32, an increase of 118.00% compared to ¥207,770,893.19 in 2020[21]. - Total assets at the end of 2021 amounted to ¥1,793,571,687.19, reflecting a 31.46% increase from ¥1,364,323,129.19 at the end of 2020[21]. - Net assets attributable to shareholders increased to ¥1,327,509,394.20, an 18.18% rise from ¥1,123,309,577.95 at the end of 2020[21]. - The comprehensive gross profit margin for 2021 was 45.34%, up 4.27 percentage points from the previous year, and the net profit margin increased to 24.39%, up 4.24 percentage points[24]. - The company achieved operating revenue of 1.167 billion RMB in 2021, representing a year-on-year growth of 75.28%[36]. - New signed orders reached 2.452 billion RMB, with a growth rate of 87.66%[38]. - The company reported a revenue increase of 15% year-over-year, reaching $1.5 billion for the fiscal year 2021[199]. Dividend and Share Capital - The company plans to distribute a cash dividend of 13.70 RMB per 10 shares, totaling approximately 85,048,980.76 RMB (including tax), which represents 30.14% of the net profit attributable to shareholders[5]. - The total share capital as of December 31, 2021, is 62,079,548 shares, with a proposed capital reserve increase of 4 shares for every 10 shares held, resulting in an additional 24,831,819 shares, bringing the total to 86,911,367 shares[5]. Audit and Compliance - The company has received a standard unqualified audit report from Lixin Certified Public Accountants[7]. - The board of directors and management have confirmed the accuracy and completeness of the annual report[4]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[9]. - The company has not violated any decision-making procedures regarding external guarantees[9]. Risks and Future Outlook - The company has outlined potential risks in its operations, which are detailed in the report's risk factors section[4]. - The company emphasizes that forward-looking statements in the report are subject to uncertainties and do not constitute substantive commitments to investors[8]. - The report includes a detailed discussion of the company's future plans and development strategies, highlighting the importance of risk awareness for investors[8]. Research and Development - The company is focused on expanding its market presence and enhancing its research and development capabilities in new drug development[13]. - The company has established a core international rule-making mechanism for drug registration, accepted by major global pharmaceutical regulatory agencies[13]. - The company is enhancing its R&D capabilities, particularly in the areas of PROTAC platform and preclinical safety evaluation technologies for biopharmaceuticals[24]. - The company has completed 85 new drug projects approved by NMPA for clinical trials during the reporting period[38]. - The company has developed multiple research platforms, including green chemistry, quality research, and safety assessment platforms, enhancing its drug development capabilities[65]. - The company is actively engaged in clinical research to validate the efficacy and safety of its drug candidates[14]. - The company has established a comprehensive preclinical drug development capability, providing one-stop services from lead compound screening to new drug clinical application submissions[63]. Workforce and Talent - The company employed 2,440 staff, a 48.60% increase, with 79.06% holding a bachelor's degree or higher[38]. - The number of R&D personnel increased to 2,117, representing 86.76% of the total workforce, up from 83.56% in the previous year[112]. - The company has cultivated a high-quality talent pool, with 1,929 employees holding a bachelor's degree or above, representing 79.06% of the total workforce, and 513 employees with master's or doctoral degrees, accounting for 21.02%[61]. - The company is committed to implementing a talent development strategy, including vocational education and collaboration with industry associations to attract high-quality professionals[183]. Market Trends and Competitive Landscape - The CRO industry is experiencing rapid growth, with the global market size projected to increase from $62.6 billion in 2019 to $96.1 billion by 2024, reflecting a compound annual growth rate (CAGR) of 8.99%[50]. - China's CRO market is expected to grow from $6.8 billion in 2019 to $22.2 billion by 2024, with a CAGR of approximately 26.5%[51]. - The domestic pharmaceutical industry is in a golden period of self-innovation, with R&D investment projected to rise from $29.8 billion in 2021 to $55.1 billion by 2026, at a CAGR of about 13.1%[51]. - The company faces increased competition from multinational CROs and domestic leaders like WuXi AppTec and Kanglongda, which may affect market expansion efforts[124]. Strategic Initiatives - The company plans to enhance its service capabilities in chemical, biological, formulation, and preclinical research to increase market share domestically and internationally[177]. - Future strategies include expanding into biopharmaceuticals and enhancing integrated preclinical research services through investments in advanced equipment and talent acquisition[178]. - The company aims to build a comprehensive drug discovery and research platform to meet the needs of large pharmaceutical enterprises[179]. - The company is committed to providing high-quality services and aims to achieve a significant increase in the proportion of comprehensive service revenue in its total income[179]. Customer Relationships and Partnerships - The company has established a professional service network in major Chinese cities, providing high-quality R&D services to numerous domestic pharmaceutical companies, including well-known firms like 恒瑞医药 and 上海医药集团[117]. - The company has a diverse international client base, including major pharmaceutical companies such as Takeda, Johnson & Johnson, and GSK, and has received accolades like the "Most Valuable Partner Award" from Roche[118]. - The company is exploring potential acquisitions to enhance its market position, with a budget of $100 million allocated for this purpose[198]. Corporate Governance - The company has established a comprehensive corporate governance structure in compliance with relevant laws and regulations, ensuring clear responsibilities and effective operations among its governance bodies[185]. - The company held three shareholder meetings during the reporting period, all conducted in accordance with legal and regulatory requirements[189].

Financial Performance - The company's operating revenue for 2021 was approximately ¥1.17 billion, representing a 75.28% increase compared to ¥665.96 million in 2020[30]. - The net profit attributable to shareholders for 2021 was approximately ¥282.22 million, an increase of 118.12% from ¥129.39 million in 2020[30]. - The net cash flow from operating activities for 2021 was approximately ¥452.94 million, reflecting a growth of 118.00% compared to ¥207.77 million in 2020[30]. - The total assets at the end of 2021 were approximately ¥1.79 billion, a 31.46% increase from ¥1.36 billion at the end of 2020[30]. - The net assets attributable to shareholders at the end of 2021 were approximately ¥1.33 billion, an 18.18% increase from ¥1.12 billion at the end of 2020[30]. - The basic earnings per share for 2021 were ¥4.55, a 117.70% increase compared to ¥2.09 in 2020[30]. - The diluted earnings per share for 2021 were also ¥4.55, reflecting the same growth rate of 117.70% from 2020[30]. - The weighted average return on equity for 2021 was 22.66%, an increase of 10.43 percentage points from 12.23% in 2020[30]. - The company achieved operating revenue of CNY 1,167.26 million, a year-on-year increase of 75.28%[173]. - The net profit attributable to shareholders reached CNY 282.22 million, up 118.12% year-on-year[173]. - The net profit after deducting non-recurring gains and losses was CNY 271.07 million, reflecting a growth of 119.53%[173]. - The net cash flow from operating activities was CNY 452.94 million, an increase of 118.00% compared to the previous year[173]. Dividend Distribution - The company plans to distribute a cash dividend of 13.70 RMB per 10 shares, totaling approximately 85,048,980.76 RMB, which represents 30.14% of the net profit attributable to shareholders[8]. - The company has not proposed any stock dividends or capital reserve transfers for the year 2021[8]. Research and Development - Research and development expenses accounted for 6.66% of operating revenue, a decrease of 0.39 percentage points compared to the previous year[32]. - The company is focusing on enhancing its R&D capabilities by investing in key technology platforms, including AI-based drug development and advanced formulation research[81]. - R&D expenses for the current year amounted to ¥77,758,296.33, representing an increase of ¥30,793,800.00 or 65.57% compared to the previous year[81]. - The company has developed a comprehensive preclinical drug R&D capability, providing one-stop services from lead compound screening to new drug clinical application submissions[68]. - The company has established a comprehensive service technology platform that meets international standards, integrating various research services including compound synthesis and toxicology safety evaluation[60]. - The company has established a high-activity laboratory and developed coupling methods for antibodies and linker-payloads in ADC drug research[42]. - The company has developed multiple raw material drug research platforms, including green chemistry and quality research platforms, to enhance drug development efficiency[72]. - The company has established a GMP-compliant oral solid preparation workshop to meet the production needs for clinical trials[72]. Market Position and Growth - The company is focused on expanding its market presence and enhancing its research capabilities in drug metabolism and pharmacokinetics[21]. - The CRO industry is projected to grow from approximately $68 billion in 2019 to $222 billion by 2024 in China, with a compound annual growth rate (CAGR) of about 26.5%[59]. - The company has established strong customer loyalty, leading to repeat collaborations with clients for new research needs[55]. - The company has built a robust marketing strategy, leveraging industry events and e-commerce platforms to expand its client base and influence[55]. - The company has established a strong international client base, including major pharmaceutical firms such as Takeda, Johnson & Johnson, and Roche, enhancing its reputation in the industry[161]. Operational Efficiency - The company has not yet achieved profitability since its listing[5]. - The company has detailed potential risks in its operations, which can be found in the "Risk Factors" section of the report[5]. - The company has received a standard unqualified audit report from its accounting firm[7]. - There are no non-operating fund occupations by controlling shareholders or related parties[10]. - The company does not have any special arrangements for corporate governance[12]. - The company has not violated decision-making procedures for providing guarantees[12]. - The company has received AAALAC certification and GLP certification from the National Medical Products Administration, highlighting its rare dual GLP qualification in the industry[60]. Client and Supplier Relations - The company has added 362 new clients during the reporting period, bringing the total number of clients to over 1,460[46]. - The top five suppliers accounted for a total procurement amount of 142.27 million RMB, representing 46.88% of the annual total procurement[194]. - The company did not rely on any single supplier for more than 50% of its total procurement, indicating a diversified supplier base[198]. Risks and Challenges - The report includes forward-looking statements that are subject to uncertainties and do not constitute substantive commitments to investors[9]. - The company faces risks related to potential loss of certifications, such as GLP and AAALAC, which could adversely affect its operations if not maintained[164]. - The company faced risks related to potential changes in tax incentives and government subsidies, which could impact profitability[173]. - The domestic CRO market is rapidly growing, with increasing competition from both international and domestic firms, necessitating continuous improvement in service capabilities[164].

Financial Performance - Revenue for Q3 2021 reached ¥301,253,455.71, an increase of 74.61% year-over-year, and total revenue for the year-to-date was ¥786,298,234.85, up 81.62% compared to the same period last year[8]. - Net profit attributable to shareholders for Q3 2021 was ¥67,850,765.16, representing a 141.67% increase year-over-year, while year-to-date net profit was ¥180,954,043.22, up 142.06% compared to the same period last year[8]. - Basic earnings per share for Q3 2021 was ¥1.09, reflecting a 142.22% increase year-over-year, with diluted earnings per share also at ¥1.09[12]. - Total operating revenue for the first three quarters of 2021 reached ¥786,298,234.85, a significant increase from ¥432,937,345.40 in the same period of 2020, representing an increase of approximately 81.5%[42]. - Net profit for the first three quarters of 2021 was ¥183,378,709.53, compared to ¥77,840,671.33 in 2020, reflecting an increase of approximately 135.4%[49]. - The total comprehensive income for the period attributable to the parent company was CNY 180,954,043.22, compared to CNY 74,756,419.87 in the same period last year, representing an increase of approximately 141.4%[50]. - Basic and diluted earnings per share were both CNY 2.92, up from CNY 1.21 in the previous year, indicating a growth of 141.3%[50]. Research and Development - Research and development expenses totaled ¥21,899,764.33 for Q3 2021, a 99.52% increase year-over-year, and accounted for 7.27% of revenue[12]. - The company continues to enhance its R&D capabilities to strengthen competitive advantages and increase business capacity[20]. - Research and development expenses for the first three quarters were ¥56,019,615.62, compared to ¥30,248,325.68 in 2020, indicating an increase of approximately 85.5%[45]. Assets and Liabilities - Total assets as of the end of Q3 2021 were ¥1,597,558,059.75, a 17.10% increase from the end of the previous year[12]. - The company's total assets increased to ¥1,597,558,059.75 from ¥1,364,323,129.19, marking a growth of about 17.1%[42]. - Non-current liabilities rose to ¥70,704,845.58 from ¥32,528,148.94, showing an increase of approximately 117.8%[42]. - The total liabilities of the company reached ¥386,930,373.15, up from ¥228,669,309.25, which is an increase of about 69.2%[42]. - Total non-current assets amounted to 665,033,566.75, a decrease from 716,835,214.07, reflecting a reduction of 7.1%[58]. - Current liabilities totaled 196,141,160.31, compared to 206,422,694.30, showing a decrease of 4.9%[61]. - Total liabilities were 228,669,309.25, down from 279,163,594.49, representing a reduction of 18.1%[61]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥201,011,355.90, reflecting a 71.42% increase compared to the same period last year[12]. - Cash inflows from operating activities totaled CNY 800,472,828.02, compared to CNY 480,815,789.06 in the same period last year, reflecting an increase of approximately 66.5%[54]. - Net cash flow from operating activities was CNY 201,011,355.90, up from CNY 117,265,411.30, marking a growth of about 71.3%[54]. - The company reported a net increase in cash and cash equivalents of negative CNY 96,371,156.12, compared to negative CNY 230,241,669.22 in the previous year, indicating an improvement in cash flow management[56]. - The company's cash and cash equivalents as of September 30, 2021, were ¥369,577,301.82, down from ¥465,948,457.94 at the end of 2020, representing a decrease of approximately 20.67%[37]. Shareholder Information - Total number of common shareholders at the end of the reporting period was 4,527[23]. - The largest shareholder, Chen Jinzhan, holds 9,722,588 shares, accounting for 15.68% of total shares[23]. - The top ten unrestricted shareholders include major investment funds, with the largest being the China Industrial Bank - Central European Medical Health Mixed Securities Investment Fund, holding 3,034,138 shares, or 4.89%[27]. - The company has not reported any significant changes in shareholder pledges or frozen shares[23]. Corporate Governance and Strategy - The company is focused on enhancing its corporate governance structure and attracting core technical personnel through an incentive plan[33]. - The company maintains a cash flow management strategy to ensure liquidity amid changing market conditions[64]. - Future outlook includes potential market expansion and new product development initiatives[64].

Financial Performance - The company reported a total revenue of RMB 200 million for the first half of 2021, representing a year-on-year increase of 25%[1] - The net profit attributable to shareholders reached RMB 50 million, up 30% compared to the same period last year[1] - The company achieved operating revenue of ¥485,044,779.14 for the first half of 2021, representing an increase of 86.26% compared to the same period last year[26] - Net profit attributable to shareholders reached ¥113,103,278.06, marking a year-on-year growth of 142.29%[26] - The net profit after deducting non-recurring gains and losses was ¥109,685,563.71, reflecting a 150.14% increase year-on-year[26] - The company has set a revenue target of 500 million RMB for the full year 2021, indicating a 20% growth expectation[20] - The company signed new orders worth ¥1,026,000,000 in the first half of 2021, with a growth rate of 93.64%[26] - The gross profit margin for the main business was 45.67%, an increase of 8.35 percentage points year-on-year[26] Market Expansion and Strategy - The company plans to expand its market presence in Europe and North America, targeting a 20% increase in market share by the end of 2022[1] - Medicilon is focusing on expanding its market presence in Europe and North America, targeting a 30% increase in international clients[20] - The company has no plans for mergers or acquisitions in the near term, focusing instead on organic growth strategies[1] - Medicilon is exploring potential mergers and acquisitions to strengthen its market position and expand its service offerings[20] Research and Development - The company has allocated RMB 30 million for R&D in the next six months, focusing on innovative drug delivery technologies[1] - The company plans to invest 50 million RMB in research and development for new technologies in the upcoming fiscal year[20] - The company achieved a total R&D investment of ¥34,119,851.29, representing a 77.04% increase compared to ¥19,271,890.81 in the previous period[53] - Research and development expenses accounted for 7.03% of operating revenue, a slight decrease of 0.37 percentage points year-on-year[26] - The company has completed 38 new drug projects approved for clinical trials by NMPA, an increase of 19 projects from 19 in the first half of 2020[52] Client Base and Demand - User data showed an increase in active clients by 15%, totaling 1,500 clients as of June 30, 2021[1] - The company has expanded its client base, now serving over 300 clients, which is a 15% increase compared to the previous year[20] - Medicilon's clinical research segment has seen a 40% increase in project volume, reflecting growing demand for its services[20] Risk Factors and Governance - Risk factors include potential regulatory changes that could impact product approvals and market access[1] - The company emphasizes its commitment to maintaining high standards of corporate governance and transparency in its operations[1] Environmental Responsibility - The company has committed to maintaining compliance with environmental standards through regular monitoring and third-party waste management[182] - The company has established a comprehensive environmental risk assessment and emergency response plan in compliance with local regulations[184] - The company has implemented solid waste management practices, including the collection and disposal of hazardous waste by qualified third parties[182] - The company has received environmental approvals for various projects, with the latest approval dated January 28, 2021[183] Workforce and Human Resources - The company employs 1,970 staff, with 1,556 (78.98%) holding a bachelor's degree or higher, and 456 (23.15%) holding master's or doctoral degrees[41] - The number of R&D personnel increased to 1,684, up from 1,246, representing a growth of 35%[128] - R&D personnel accounted for 85.48% of the total workforce, an increase from 83.40%[128] - Total compensation for R&D personnel reached ¥110,143,599.19, compared to ¥81,520,857.33 in the previous period, marking a 35% increase[128] Technological Advancements - The company has developed advanced technologies in modern synthetic chemistry, particularly in chiral drugs, glycosylation, and antibody-drug conjugates (ADCs)[45] - The company has established a comprehensive service technology platform that includes compound synthesis, activity screening, structural biology, and toxicology safety evaluation, meeting international standards[41] - The PROTAC technology is reported to effectively target nearly 100% of drug targets, showcasing its revolutionary potential in the pharmaceutical industry[113] Financial Health and Investments - The company’s total assets were reported at 1,488.78 million yuan, with operating revenue of 485.04 million yuan, reflecting rapid business growth and expansion[143] - The company’s investment activities resulted in a net cash outflow of 136.60 million yuan, primarily due to the construction of new laboratories[152] - The company’s financing activities led to a net cash outflow of 74.98 million yuan, mainly due to cash dividend distribution and acquisition payments[153]

Financial Performance - Operating revenue for the period was ¥214,726,795.49, representing a 102.81% increase year-on-year[12]. - Net profit attributable to shareholders was ¥45,118,700.74, a significant increase of 195.70% compared to the same period last year[12]. - Basic earnings per share increased to ¥0.73, reflecting a growth of 192.00% compared to the previous year[12]. - Net profit for Q1 2021 was ¥47,403,100.16, representing a 206.5% increase from ¥15,465,601.25 in Q1 2020[49]. - Total operating revenue for Q1 2021 reached ¥214,726,795.49, a significant increase of 102.5% compared to ¥105,877,593.97 in Q1 2020[47]. Cash Flow - Net cash flow from operating activities was ¥22,276,276.28, up 338.72% year-on-year[12]. - The net cash flow from operating activities for Q1 2021 was ¥22,000,672.48, a significant increase from ¥3,627,233.92 in Q1 2020, representing a growth of approximately 507%[59]. - The cash inflow from operating activities totaled ¥192.13 million in Q1 2021, compared to ¥113.10 million in Q1 2020, representing an increase of 69.9%[54]. - The cash outflow from operating activities was ¥169.85 million in Q1 2021, up from ¥108.02 million in Q1 2020, which is a 57.2% increase[57]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,456,002,298.38, an increase of 6.72% compared to the end of the previous year[12]. - Total liabilities amounted to ¥270,429,662.25, compared to ¥228,669,309.25, showing an increase of around 18.2%[37]. - Current assets totaled ¥698,944,415.47, slightly down from ¥699,289,562.44, indicating a decrease of about 0.05%[32]. - Non-current assets rose to ¥757,057,882.91 from ¥665,033,566.75, reflecting an increase of approximately 13.8%[35]. - Total liabilities increased to ¥239,854,004.88 in the latest report, compared to ¥194,052,299.87 previously, marking a 23.6% rise[43]. Research and Development - The proportion of R&D investment to operating revenue decreased to 7.15%, down 1.06 percentage points from the previous year[12]. - R&D expenses increased by 76.6% to ¥15,358,165.05, reflecting the company's investment in enhancing research capabilities[26]. - Research and development expenses for Q1 2021 totaled ¥15,358,165.05, up 76.5% from ¥8,696,529.27 in Q1 2020[47]. Shareholder Information - The total number of shareholders at the end of the reporting period was 3,904[18]. - The top shareholder, Chen Jinzhuang, holds 15.68% of the shares, totaling 9,722,588 shares[18]. - Shareholders' equity reached ¥1,185,572,636.13, up from ¥1,135,653,819.94, indicating a growth of about 4.4%[37]. Expenses - Sales expenses increased by 46.74% to ¥9,083,463.78, primarily due to intensified market expansion efforts[26]. - The company reported a decrease in financial expenses to -¥2,014,144.07, a reduction attributed to improved cash management[26]. - The gross profit margin improved significantly, with operating costs rising by 79.89% to ¥122,011,811.68, driven by increased personnel costs and direct materials[24].

Financial Performance - The company achieved operating revenue of CNY 665,955,931.75, representing a 48.19% increase compared to CNY 449,392,825.85 in 2019[31]. - The net profit attributable to shareholders for 2020 was CNY 129,386,307.58, a 94.35% increase from CNY 66,573,120.12 in 2019[31]. - The net cash flow from operating activities for 2020 was CNY 207,770,893.19, showing a significant increase of 256.39% compared to CNY 58,299,144.52 in 2019[31]. - The total assets at the end of 2020 were CNY 1,364,323,129.19, a 20.92% increase from CNY 1,128,319,614.99 at the end of 2019[31]. - The net profit after deducting non-recurring gains and losses for 2020 was CNY 123,478,266.11, which is an increase of 111.39% from CNY 58,411,632.24 in 2019[31]. - The company plans to distribute a cash dividend of 6.30 RMB per 10 shares, totaling 39,060,000 RMB (including tax) based on a total share capital of 62,000,000 shares as of December 31, 2020[8]. - The cash dividend represents 30.19% of the net profit attributable to the shareholders of the parent company for the year 2020[8]. Audit and Compliance - The company received a standard unqualified audit report from Lixin Certified Public Accountants[7]. - The board of directors and senior management confirm the accuracy and completeness of the annual report[4]. - The company does not have any non-operating fund occupation by controlling shareholders or related parties[10]. - There are no violations of decision-making procedures regarding external guarantees[10]. - The company has not experienced any issues with a majority of directors being unable to ensure the authenticity of the annual report[12]. - The report includes forward-looking statements that are subject to uncertainties and do not constitute a substantive commitment to investors[9]. Research and Development - The company’s strategic focus includes expanding its research and development capabilities in drug metabolism and pharmacokinetics[24]. - The company invested 7.05% of its operating revenue in R&D, up by 0.78 percentage points from the previous year[33]. - The average output value per R&D personnel increased to CNY 560,300, a rise of 10.01% year-on-year[33]. - The company is enhancing its R&D capabilities in areas such as PROTAC technology and preclinical safety evaluation for biopharmaceuticals[33]. - The company has established a comprehensive preclinical drug development capability, providing one-stop services from lead compound screening to clinical trial application[61]. - The company has developed advanced technologies in modern synthetic chemistry, drug discovery, and pharmacokinetics, enhancing the efficiency of drug development[61]. - The company has established a PROTAC technology platform that can support over 10 PROTAC research projects annually, enhancing the efficiency of drug development[22]. Market Position and Strategy - The company aims to enhance its market presence through potential mergers and acquisitions in the biopharmaceutical sector[24]. - The company is recognized for its dual reporting capabilities under both Chinese and U.S. GLP standards, which is a significant competitive advantage in the preclinical CRO sector[54]. - The global CRO market is projected to reach $64.58 billion by 2021, with a compound annual growth rate (CAGR) of 12.8% from 2016 to 2021[51]. - China's CRO market size is expected to grow from $6.8 billion in 2019 to $22.2 billion by 2024, with a CAGR of approximately 26.5%[51]. - The company has established a professional service network in major Chinese cities, providing high-quality R&D services to leading domestic pharmaceutical companies[115]. - The company has accumulated a diverse international client base, including renowned pharmaceutical firms such as Takeda, Johnson & Johnson, and GSK, enhancing its global presence[116]. Operational Efficiency - The company has a comprehensive procurement process for laboratory animals, reagents, and equipment, ensuring quality control and compliance with internal regulations[47]. - The company has established three service models: product customization, design and development, and collaborative research, ensuring high-quality and efficient drug development[48]. - The company actively participates in industry exhibitions and academic seminars to expand its client base and enhance its influence in the market[50]. - The company has built a GMP-compliant raw material drug research platform, successfully developing innovative and generic drug raw materials for multiple pharmaceutical companies[63]. Talent and Workforce - The company employs 1,642 staff, with 80.39% holding a bachelor's degree or higher, and 26.67% holding a master's or doctoral degree[54]. - The number of R&D personnel increased to 1,372, representing 83.56% of the total workforce, up from 82.12% in the previous period[107]. - The total compensation for R&D personnel reached 18,148.55 million RMB, with an average salary of 15.28 million RMB, compared to 12,741.83 million RMB and 14.46 million RMB respectively in the previous period[107]. - The company emphasizes talent acquisition, planning to recruit high-level professionals in chemistry, drug formulation, oncology research, pharmacokinetics, and toxicology over the next few years[195]. Future Outlook - The company plans to continue expanding its research and development capabilities to drive future growth[142]. - Future strategies include expanding the PROTAC research team by 50%-100% and establishing a high-standard drug discovery laboratory to serve international clients[192]. - The company intends to invest in advanced equipment and attract experienced talent to strengthen its capabilities in biopharmaceutical research[191]. - The company will enhance its employee training system to improve overall business capabilities and leadership skills among staff and management[195]. - The company is committed to a "people-oriented" development strategy, focusing on talent cultivation and retention[195].